Positive results were reported in the Phase 1 trial of intravitreal drug 4D-150 for the treatment of wet age-related macular degeneration (AMD).
The new drug is manufactured by 4D Molecular Therapeutics and is a dual-transgene intravitreal gene therapy. Five patients received a dose of 3E10 vg per eye, five received 1E10 vg per eye and five received 6E9 vg per eye.
Following up at 24 weeks, all patients had tolerated the injections well and 14 patients had experienced no inflammation after treatment. No serious adverse events were reported. While all three doses demonstrated improvement in patients' eyes, the 3E10 vg per eye showed the most meaningful improvement in mean central subfield thickness and stable mean best corrected visual acuity. An added plus was that four of the five patients did not have to receive a supplemental afibercept injection.
Phase 2 of the trial will be the dose-expansion phase of the trial and will include 50 participants and is expected to be completed later this year.
